Endo Pharmaceuticals (ENDP) to commercialize FORTESTA(TM) with ProStrakan
Endo Pharmaceuticals (Nasdaq: ENDP) signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.